文献速递脑血管病

急性缺血性卒中患者高血糖的强化与标准治疗:一项随机临床试验的亚组分析

Intensive Versus Standard Treatment of Hyperglycemia in Acute Ischemic Stroke Patient: A Randomized Clinical Trial Subgroups Analysis.
PubMed 文献 · Stroke · 2022-03-25

SHINE试验将1151例急性缺血性卒中合并高血糖患者随机分配至标准血糖控制组(目标80-179 mg/dL)或强化组(目标80-130 mg/dL)治疗72小时。预设亚组分析显示,强化与标准治疗在90天功能结局上无差异,且各血糖参数与功能结局无关联;未确诊糖尿病患者获得良好结局的可能性最低(校正相对风险0.42,99%CI 0.19-0.94)。

要点

  • 在预设的血糖参数亚组中,强化与标准胰岛素治疗对90天功能结局无差异。
  • 未确诊糖尿病患者较真非糖尿病患者获得良好结局的可能性更低(校正相对风险0.42,99%CI 0.19-0.94)。
  • 基线血糖及其他血糖参数与90天功能结局无关联。

核心结论

  • 在这项探索性亚组分析中,急性缺血性卒中患者亚组接受强化与标准胰岛素治疗高血糖,未影响90天功能结局,也未发现这些血糖参数与90天功能结局的关联。

研究设计与样本

  • SHINE试验将1151例12小时内急性缺血性卒中合并高血糖患者随机分配至标准血糖控制组(目标80-179 mg/dL)或强化组(目标80-130 mg/dL)治疗72小时。
  • 预设6项血糖参数:急性血糖水平、确诊与未确诊糖尿病的缺失与存在、血红蛋白A1c、血糖间隙、应激性高血糖比率、血糖变异性(标准差)。
  • 良好功能结局由SHINE试验定义,基于90天改良Rankin量表评分,并校正卒中严重程度。
  • 计算校正基线卒中严重程度和溶栓使用的相对风险。

主要发现

  • 未确诊糖尿病患者较真非糖尿病患者获得良好结局的可能性最低(校正相对风险0.42,99%CI 0.19-0.94)。
  • 未发现良好结局率与基线血糖或任何血糖参数之间的关系。
  • 在任何这些患者亚组中,未发现SHINE治疗组间的差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benefit from blood glucose (BG) control during acute ischemic stroke may depend on glycemic parameters. We evaluated for associations between the SHINE (Stroke Hyperglycemia Insulin Network Effort) randomized treatment group and the SHINE predefined 90-day functional outcome, within-patient subgroups defined by various glycemic parameters. METHODS: The SHINE Trial randomized 1151 patients within 12 hours with acute ischemic stroke and hyperglycemia to standard (target BG 80-179 mg/dL) or intensive (target BG 80-130 mg/dL) BG control for 72 hours. We predefined 6 glycemic parameters: acute BG level, absence versus presence of diagnosed and undiagnosed diabetes, hemoglobin A1c, glycemic gap (acute BG-average daily hemoglobin A1c based BG), stress hyperglycemia ratio (acute BG/average daily hemoglobin A1c based BG), and BG variability (SD). Favorable functional outcome was defined by the SHINE Trial and based on the modified Rankin Scale score at 90 days, adjusted for stroke severity. We computed relative risks adjusted for baseline stroke severity and thrombolysis use. RESULTS: Likelihood for favorable outcome was lowest among patients with undiagnosed diabetes compared to patients with true nondiabetes (adjusted relative risk, 0.42 [99% CI, 0.19-0.94]). We did not find any relationship between the favorable outcome rate and baseline BG or any of the glycemic parameters. No differences between SHINE treatment groups were identified among any of these patient subgroups. CONCLUSIONS: In this exploratory subgroup analysis, intensive versus standard insulin treatment of hyperglycemia in acute ischemic stroke patient subgroups, did not influence the 90-day functional outcomes, nor did we identify associations between these glycemic parameters and 90-day functional outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Torbey MT, Pauls Q, Gentile N, et al. Intensive Versus Standard Treatment of Hyperglycemia in Acute Ischemic Stroke Patient: A Randomized Clinical Trial Subgroups Analysis. Stroke. 2022. PMID: 35331007. doi:10.1161/STROKEAHA.120.033048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。